comprehensive
An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.
The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.
advertisement
In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$30
for 3 months, then $39/month
$30 for 3 months Get StartedThen $39/month
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log InNext article： Continuity nursing helped my family in our darkest PICU moments
